Medications for Brain Disorders
For cognitive impairment from Alzheimer's disease or dementia, start with a cholinesterase inhibitor—specifically donepezil 5 mg daily, which offers the best tolerability and once-daily dosing—and expect only modest benefits (equivalent to delaying decline by approximately one year). 1
Primary Treatment Options by Condition
Alzheimer's Disease and Dementia
Mild to Moderate Disease:
- First-line: Cholinesterase inhibitors are recommended 2, 3
- Donepezil (Aricept): Start 5 mg once daily, increase to 10 mg after 4 weeks. Not hepatotoxic. Take with food to minimize nausea, vomiting, diarrhea 1
- Rivastigmine (Exelon): Start 1.5 mg twice daily, titrate by 3 mg/day every 4 weeks to maximum 6-12 mg/day. More side effects but no liver monitoring needed 1
- Galantamine (Reminyl): Start 4 mg twice daily with meals, increase to 8 mg twice daily after 4 weeks, consider 12 mg twice daily based on response 1
- Avoid tacrine: Requires four-times-daily dosing and causes liver enzyme elevation in 40% of patients, necessitating frequent monitoring 1, 2
Moderate to Severe Disease:
- Memantine: 20 mg/day for moderate to severe Alzheimer's disease 2, 4
- Combination therapy: Memantine plus donepezil is recommended for severe Alzheimer's disease 3
Vascular Cognitive Impairment
- Cholinesterase inhibitors and memantine may be considered in selected patients 4
- Critical: Treat underlying hypertension aggressively—target systolic BP <120 mmHg in middle-aged/older persons with vascular risk factors to reduce MCI risk 4
- Guideline-recommended stroke prevention treatments are mandatory 4
Lewy Body Dementias
- Cholinesterase inhibitors should be used for both Parkinson's disease dementia and dementia with Lewy bodies 5
- Memantine may be helpful 5
Frontotemporal Dementia
- Do not use cholinesterase inhibitors—they are ineffective and may cause agitation 5
- SSRIs may help behavioral (not cognitive) features 5
Setting Realistic Expectations
The benefits are modest at best. Cholinesterase inhibitors produce:
- 7-point improvement on neuropsychologic tests (equivalent to one year's decline) 1
- 5-15% benefit over placebo 1
- Only 20-35% of patients show any response 1
- Statistically significant but clinically marginal improvements 6
Before prescribing, explicitly communicate these limited benefits to patients and families 1. The average improvement does not reach clinically significant levels, though a subset of patients may experience meaningful benefit 2.
Choosing Between Medications
Base your choice on tolerability, side effect profile, ease of use, and cost—not efficacy, as no head-to-head studies show superiority of one agent over another 1, 2.
Practical algorithm:
- Start with donepezil for best tolerability and once-daily dosing 1
- If intolerable side effects develop, switch to another cholinesterase inhibitor—patients who don't respond to one may respond to another 1
- For moderate-to-severe disease, add or switch to memantine 2
Monitoring and Duration
- Assess response at 6-12 months using physician global assessment, caregiver report, or neuropsychologic testing 1
- Brief mental status tests are relatively insensitive for detecting drug effects 1
- Discontinue if:
- Do not stop just because dementia severity increases—continue treatment in moderate-to-severe disease 5
Common Pitfalls to Avoid
- Don't screen asymptomatic individuals—cognitive testing in asymptomatic adults (even with risk factors) is not recommended 4
- Don't use in mild cognitive impairment—neither cholinesterase inhibitors nor memantine are effective 5
- Don't expect disease modification—these drugs provide symptomatic benefit only, not cure 3, 6
- Don't overlook contraindications: uncontrolled asthma, angle-closure glaucoma, sick sinus syndrome, left bundle-branch block 2
Other Brain Conditions
Traumatic Brain Injury:
- Amantadine promotes neurologic recovery when given 4-16 weeks post-injury (strongest evidence) 7, 8
- Dopaminergic agents (bromocriptine, levodopa) may improve alertness in disorders of consciousness 8, 9
Behavioral symptoms in TBI: